In January, Eli Lilly acquired Cialis' maker, ICOS Corp. for $2.3 billion. The second quarter return is the first full period incorporating Cialis profits into Eli Lilly's numbers. The take-over kicked marketing and administrative expenses up 23 percent to $1.52 billion."We are very pleased to have delivered another quarter of strong financial results," CEO Sidney Taurel said. "Our accelerated, double-digit sales growth in this quarter was fueled by increased volume, driven by several products launched this decade, most notably Cymbalta."
